Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
Form 4 overview: Orchestra BioMed Holdings, Inc. (ticker OBIO) reported an insider transaction by Principal Accounting Officer Joshua Aiello on 06/18/2025.
Key details: 393 shares of "Common Stock, $0.0001 par value" were withheld (Transaction Code F) at a price of $2.99 per share to cover tax obligations triggered by the vesting of restricted stock units. No shares were sold on the open market.
Post-transaction ownership: Mr. Aiello now directly owns 4,329 OBIO shares. No derivative securities were reported, and no 10b5-1 trading plan box was marked.
Investor take-away: Code F transactions are administrative and typically have negligible market impact because they do not reflect discretionary buying or selling. The filing neither alters the company’s fundamentals nor signals a shift in insider sentiment.